Drug profile · INN
surufatinib
SEVSURY
surufatinib (SEVSURY) is a vascular endothelial growth factor receptor inhibitor.
EMA: application withdrawn NMPA: clinical trials Antineoplastic and immunomodulating agents (L01) L01EX01
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — surufatinib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 3
- Data quality
- 0.83
Quick answer
surufatinib (SEVSURY) is a vascular endothelial growth factor receptor inhibitor.
Key facts
INN surufatinib
Brand SEVSURY
Mechanism Vascular endothelial growth factor receptor inhibitor
Target Fibroblast growth factor receptor 1
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01EX01
Mechanism of action
Vascular endothelial growth factor receptor inhibitor
Primary target: Fibroblast growth factor receptor 1
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | application withdrawn | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is surufatinib?
surufatinib (SEVSURY) is a vascular endothelial growth factor receptor inhibitor.
What is the brand name for surufatinib?
SEVSURY is a marketed brand name for surufatinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.